EGFR Mutation and TKI Treatment Promote Secretion of Small Extracellular Vesicle PD-L1 and Contribute to Immunosuppression in NSCLC
Biomolecules · 09.07.2024 · 14 (7) · 820
DOI: 10.3390/biom14070820 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 09.07.2024. Verfasst von Hai-Ming Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Lab…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, B7-H1 Antigen, Extracellular Vesicles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
In Asian populations with non-small-cell lung cancer (NSCLC), EGFR mutations are highly prevalent, occurring in roughly half of these patients. Studies have revealed that individuals with EGFR mutation typically fare worse with immunotherapy. In patients who received EGFR tyrosine kinase inhibitor (TKI) treatment followed by anti-PD-1 therapy, poor results were observed. The underlying mechanism remains unclear. We used high-resolution flow cytometry and ELISA to detect the circulating level of small extracellular vesicle (sEV) PD-L1 in NSCLC individuals with EGFR mutations before and after receiving TKIs. The secretion amount of sEV PD-L1 of lung cancer cell lines with EGFR mutations under TKI treatment or not were detected using high-resolution flow cytometry and Western blotting. The results revealed that patients harboring EGFR mutations exhibit increased levels of sEV PD-L1 in circulation, which inversely correlated with the presence of CD8+ T cells in tumor tissues. Furthermore, tumor cells carrying EGFR mutations secrete a higher quantity of PD-L1-positive sEVs. TKI treatment appeared to amplify the levels of PD-L1-positive sEVs in the bloodstream. Mutation-induced and TKI-induced sEVs substantially impaired the functionality of CD8+ T cells. Importantly, our findings indicated that EGFR mutations and TKI therapies promote secretion of PD-L1-positive sEVs via distinct molecular mechanisms, namely the HRS and ALIX pathways, respectively. In conclusion, the increased secretion of PD-L1-positive sEVs, prompted by genetic alterations and TKI administration, may contribute to the limited efficacy of immunotherapy observed in EGFR-mutant patients and patients who have received TKI treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School and Hospital of Stomatology, Wuhan Univ…
- Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China.
- TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China.
- Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, China.
ORCID-Profile: Zi-Li Yu
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- Fundamental Research Funds for the Central Universities
- Interdisciplinary Research Project of School of Stomatology Wuhan University
Zitieren
APA
Liu, H. M., Yu, Z. L., Xia, H. F., Zhang, L. Z., Fu, Q. Y., Wang, Y., Gong, H. Y., & Chen, G. (2024). EGFR Mutation and TKI Treatment Promote Secretion of Small Extracellular Vesicle PD-L1 and Contribute to Immunosuppression in NSCLC. Biomolecules, 14(7), 820. https://doi.org/10.3390/biom14070820
Vancouver
Liu HM, Yu ZL, Xia HF, Zhang LZ, Fu QY, Wang Y, et al. EGFR Mutation and TKI Treatment Promote Secretion of Small Extracellular Vesicle PD-L1 and Contribute to Immunosuppression in NSCLC. Biomolecules. 2024;14(7):820. doi:10.3390/biom14070820
BibTeX
@article{Liu2024,
author = {Liu, Hai-Ming and Yu, Zi-Li and Xia, Hou-Fu and Zhang, Lin-Zhou and Fu, Qiu-Yun and Wang, Yi and Gong, Hong-Yun and Chen, Gang},
title = {EGFR Mutation and TKI Treatment Promote Secretion of Small Extracellular Vesicle PD-L1 and Contribute to Immunosuppression in NSCLC},
journal = {Biomolecules},
year = {2024},
volume = {14},
number = {7},
pages = {820},
doi = {10.3390/biom14070820}
}
EUVIMED